All-cause mortality in a cohort of 2-year survivors after autologous HCT. (A) Sex-specific survival for hematologic malignancies for the entire cohort. (B) Mortality for hematologic malignancies for the entire cohort by risk of relapse at HCT. (C) Mortality for acute myeloid leukemia at standard risk for relapse at HCT. Few patients in the high-risk category prevented us from presenting results in the high-risk category. (D) Mortality for Hodgkin disease by risk of relapse at HCT. (E) Mortality for non-Hodgkin lymphoma by risk of relapse at HCT. (F) Mortality for acute lymphoblastic leukemia by risk of relapse at HCT.